SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Mateos María Victoria) "

Sökning: WFRF:(Mateos María Victoria)

  • Resultat 1-5 av 5
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Kehoe, Laura, et al. (författare)
  • Make EU trade with Brazil sustainable
  • 2019
  • Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 364:6438, s. 341-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
2.
  • Hudson, Lawrence N, et al. (författare)
  • The database of the PREDICTS (Projecting Responses of Ecological Diversity In Changing Terrestrial Systems) project
  • 2017
  • Ingår i: Ecology and Evolution. - : John Wiley & Sons. - 2045-7758. ; 7:1, s. 145-188
  • Tidskriftsartikel (refereegranskat)abstract
    • The PREDICTS project-Projecting Responses of Ecological Diversity In Changing Terrestrial Systems (www.predicts.org.uk)-has collated from published studies a large, reasonably representative database of comparable samples of biodiversity from multiple sites that differ in the nature or intensity of human impacts relating to land use. We have used this evidence base to develop global and regional statistical models of how local biodiversity responds to these measures. We describe and make freely available this 2016 release of the database, containing more than 3.2 million records sampled at over 26,000 locations and representing over 47,000 species. We outline how the database can help in answering a range of questions in ecology and conservation biology. To our knowledge, this is the largest and most geographically and taxonomically representative database of spatial comparisons of biodiversity that has been collated to date; it will be useful to researchers and international efforts wishing to model and understand the global status of biodiversity.
  •  
3.
  • Mateos, María-Victoria, et al. (författare)
  • Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
  • 2017
  • Ingår i: Haematologica. - : Ferrata Storti Foundation (Haematologica). - 1592-8721 .- 0390-6078. ; 102:10, s. 1767-1775
  • Tidskriftsartikel (refereegranskat)abstract
    • Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd. Patients with relapsed/refractory multiple myeloma received ixazomib-Rd or placebo-Rd. Efficacy and safety were evaluated in subgroups defined according to type (proteasome inhibitor [PI] and immunomodulatory drug) and number (1 vs. 2 or 3) of prior therapies received. Of 722 patients, 503 (70%) had received a prior PI, and 397 (55%) prior lenalidomide/thalidomide; 425 patients had received 1 prior therapy, and 297 received 2 or 3 prior therapies. At a median follow up of ~15 months, PFS was prolonged with ixazomib-Rd vs. placebo-Rd regardless of type of prior therapy received; HR 0.739 and 0.749 in PI-exposed and -naïve patients, HR 0.744 and 0.700 in immunomodulatory-drug-exposed and -naïve patients, respectively. PFS benefit with ixazomib-Rd vs. placebo-Rd appeared greater in patients with 2 or 3 prior therapies (HR 0.58) and in those with 1 prior therapy without prior transplant (HR 0.60) versus those with 1 prior therapy and transplant (HR 1.23). Across all subgroups, toxicity was consistent with that seen in the intent-to-treat population. In patients with relapsed/refractory multiple myeloma, ixazomib-Rd was associated with a consistent clinical benefit vs. placebo-Rd regardless of prior treatment with bortezomib or immunomodulatory drugs. Patients with 2 or 3 prior therapies, or 1 prior therapy without transplant seemed to have greater benefit than patients with 1 prior therapy and transplant. TOURMALINE-MM1 registered at clinicaltrials.gov identifier: 01564537.
  •  
4.
  • Mateos, Maria-Victoria, et al. (författare)
  • Melflufen : A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
  • 2020
  • Ingår i: Journal of Clinical Medicine. - : MDPI AG. - 2077-0383. ; 9:10
  • Forskningsöversikt (refereegranskat)abstract
    • Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options after second-line treatment. Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Once inside the tumor cells, melflufen is hydrolyzed by peptidases to release alkylator molecules, which become entrapped. Melflufen showed anti-myeloma activity in myeloma cells that were resistant to bortezomib and the alkylator melphalan. In early phase studies (O-12-M1 and HORIZON [OP-106]), melflufen plus dexamethasone has demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma, including those with triple-class refractory disease and extramedullary disease. The Phase III OCEAN study (OP-104) is further evaluating melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma. The safety profile of melflufen is characterized primarily by clinically manageable hematologic adverse events. Melflufen, with its novel mechanism of action, has the potential to provide clinically meaningful benefits to patients with relapsed/refractory multiple myeloma, including those with high unmet needs.
  •  
5.
  • Morabito, Fortunato, et al. (författare)
  • Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
  • 2014
  • Ingår i: American Journal of Hematology. - : Wiley. - 0361-8609. ; 89:4, s. 355-362
  • Tidskriftsartikel (refereegranskat)abstract
    • Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-5 av 5
Typ av publikation
tidskriftsartikel (4)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (4)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Jung, Martin (2)
Tscharntke, Teja (2)
Hylander, Kristoffer (1)
Granjon, Laurent (1)
Rothhaupt, Karl-Otto (1)
Beksac, Meral (1)
visa fler...
Waage, Anders (1)
Hansson, Markus (1)
Abrahamczyk, Stefan (1)
Weigend, Maximilian (1)
Jonsell, Mats (1)
Brunet, Jörg (1)
Kolb, Annette (1)
Farrell, Katharine N ... (1)
Islar, Mine (1)
Krause, Torsten (1)
Uddling, Johan, 1972 (1)
Alexanderson, Helena (1)
Sáfián, Szabolcs (1)
Schneider, Christoph (1)
Battiston, Roberto (1)
Juliusson, Gunnar (1)
Lukic, Marko (1)
Pereira, Laura (1)
Persson, Anna S. (1)
Riggi, Laura (1)
Cattaneo, Claudio (1)
Franzén, Markus (1)
Andresen, Louise C. (1)
Kasimir, Åsa (1)
Nilsson, Sven G (1)
Wang-Erlandsson, Lan (1)
Hamadani, Mehdi (1)
Sutherland, William ... (1)
Berg, Åke (1)
Boonstra, Wiebren J. (1)
Vajda, Vivi (1)
Pascual, Unai (1)
Entling, Martin H. (1)
Goulson, Dave (1)
Herzog, Felix (1)
Knop, Eva (1)
Aizen, Marcelo A. (1)
Petanidou, Theodora (1)
Stout, Jane C. (1)
Woodcock, Ben A. (1)
Brown, Calum (1)
Peterson, Gustaf (1)
Meyer, Carsten (1)
Poveda, Katja (1)
visa färre...
Lärosäte
Lunds universitet (4)
Sveriges Lantbruksuniversitet (2)
Umeå universitet (1)
Kungliga Tekniska Högskolan (1)
Uppsala universitet (1)
Stockholms universitet (1)
visa fler...
Mittuniversitetet (1)
Chalmers tekniska högskola (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (5)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (3)
Naturvetenskap (2)
Teknik (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy